La protéine Stat3

CLEVELAND, Feb. 20 (UPI)
Des généticiens ont découvert un chemin cellulaire qui joue un rôle critique dans le développement du cancer du

Ce chemin cellulaire pourrait aussi jouer un rôle dans le développement du cancer de l'estomac et du

Les chercheurs ont identifié STAT3, un tranducteur de signaux et un activateur de la transcription 3(?) qui avait été identifié auparavant comme muté pour les cacens du

du

et de l'estomac.

"Nos études montrent que le recepteur de protéine kyrosine phosphate T régule un important chemin cellulaire qui est critique pour le développement du cancer" dit Wang " Cette identification nous permettra de nouvelles approches pharmaceutiques et facilitera les approches alternatives pour le traitement du cancer.

(Jun. 2, 2008) — Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination. The work opens the door to future studies examining the protein as a target for therapies aimed at keeping prostate cancer at bay.

Les chercheurs ont démontré qu'en bloquant une protéine, ils peuvent arrêter les cellules cancéreuses dela de se disséminer. Le travail ouvre la porte à de futures études qui examineraient cette protéine comme cible pour une thérapie ciblée pour garder le cancer ou il est.

In a series of experiments in both the laboratory and animal models, Marja Nevalainen, M.D., Ph.D., associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and her co-workers found that the protein, Stat3, is key to the metastatic progression of prostate cancer. Dr. Nevalainen's group reports its findings in the June 2008 issue of the American Journal of Pathology.

La protéine stat3 est une protéine clé pour le cancer de la prostate.

According to Dr. Nevalainen, previous studies have shown that Stat3 is very active in metastatic prostate cancer, and the protein has been linked to cancer metastasis in several different cancer types. Because metastatic prostate cancer lacks effective therapies, understanding the molecular changes involved is critical.

La protéien stat3 est trèa cative dans le cancer de la prostate et la protéine a été relié auparavant à beaucoup de cancer. Parce que le cancer de la prostaet manque de thérapies efficaces, comprendre les changements moléculaires impliquées est important.

To clarify Stat3's role in prostate cancer progression, she and her co-workers performed several studies. In one case, the scientists used an antibody for Stat3, for example, to show that it is activated in 77 percent of lymph nodes and 66 percent of bone metastases in human prostate cancer. In another experiment, the scientists prompted mouse prostate cancer cells to overproduce the normal Stat3 protein by delivering it through a virus vehicle. They saw a dramatic increase in prostate cancer metastases compared to controls.

Specifically, in mice lacking a working immune system, they showed that Stat3 caused a 33-fold increase in metastases.

"This is the first proof that Stat3 may have a major effect on metastatic dissemination of prostate cancer," Dr. Nevalainen says. "Stat3 now becomes a potential drug target to interfere with the metastatic progression of prostate cancer."

While her team's results "open up other opportunities to study the mechanism of prostate cancer metastases," Dr. Nevalainen notes that Stat3 might have possible use in the prevention of primary prostate cancer from progressing to metastatic disease as well.

She suggests that studies testing newly developed Stat3 inhibitors in prostate cancer should include testing their effectiveness in blocking prostate cancer metastases in experimental animal models.

elle suggère que les études sur les inhibiteurs de stats3 nouvellement développé pourrait inclure de tester l'efficacité quant à l'arrêt des métastases.